TABLE 2.
Lymphoma Characteristics
| Case | Morphology | Immunophenotype | EBV | Ph/Ge | IgH | Cytogenetics | MYC |
|---|---|---|---|---|---|---|---|
| 1 | Large | CD45, CD19, CD20, CD22, HLA-DR | − | B | R | NA | NA |
| 2 | Large, pleomorphic | CD45, CD30, LLC | + | B | NA | NA | G |
| 3 | Large, pleomorphic | KLC | − | B | NA | NA | G |
| 4 | Large | CD45, CD19, CD20, CD22, LLC | − | B | R | t(9:14) & complex karyotype | G |
| 5 | Immunoblastic | CD19, LLC | − | B | R | NA | NA |
| 6 | Large, pleomorphic | CD45, CD7, CD19, CD20, CD22, HLA-DR | + | B | NA | Complex | G |
| 7 | Large, pleomorphic | CD19, CD20, CD22 | − | B | R | NA | G |
| 8 | Large | CD3, CD7, TCR α-β | NA | T | NA | del(1) (p11p22), +i(7)(ql0), and t(11:14)(q23;q11) | NA |
| 9 | Medium to large | CD19, CD20, LLC | + | B | R | NA | NA |
| 10 | Pleomorphic | CD4, CD5, CD19, CD20 | − | B | R | Hyperdiploid | R |
| 11 | Large | CD19, CD20, HLA-DR, KLC, IgM | − | B | R | Complex | G-A |
| 12 | Large | CD10, CD19, CD20, HLA-DR | − | B | R | Complex | G-A |
| 13 | Large | CD5, CD10, CD19, CD20, HLA-DR | − | B | R | Complex | G-A |
| 14 | Large, pleomorphic | CD45, CD10, CD19, CD20, CD22, FMC7, HLA-DR, KLC | − | B | R | NA | NA |
| 15 | Large, pleomorphic | CD19, CD20, CD22, HLA-DR | + | B | NA | No anomalies | G |
| 16 | Large, pleomorphic | CD20, CD79a, BCL2 | − | B | R | NA | R |
| 17 | Medium to large | CD19, CD20, CD45, CD79a | − | B | R | 46XY | NA |
| 18 | Large, plasmacytoid | CD20, CD38, CD45, CD79a, IgM, KLC | + | B | R | Complex | G |
| 19 | Large, pleomorphic | CD45, CD8, CD10, CD19, CD20, CD22, CD24, CD71, HLA-DR | − | B | R | Complex | G |
| 20 | NA | CD45, CD19, CD20, CD25, HLA-DR, KLC | − | B | R | NA | G-A |
| 21 | Large, pleomorphic | CD10, CD19, CD20, HLA-DR | − | B | NA | Complex | G-A |
| 22 | Large | CD20, CD79a | − | B | R | t(1;22)(q21;q11),t(14;17)(q32;q23) | G |
| 23 | Medium to large, plasmacytoid | CD38, CD138 | NA | ID | NA | NA | NA |
| 24 | Large, pleomorphic | CD19, CD20, CD30 | NA | B | R | Complex | R |
| 25 | Large | CD19, CD20, CD30, KLC | NA | B | NA | NA | NA |
| 26 | Immunoblastic to anaplastic | CD45, CD3, CD8, CD30 | − | T | TCR | NA | NA |
| 27 | Large, pleomorphic | CD45, CD20, CD30, CD79a | NA | B | NA | NA | NA |
| 28 | Large, pleomorphic | CD20, CD79a | NA | B | R | NA | G |
| 29 | Large, pleomorphic | CD19, CD20, CD22, HLA-DR, LLC, IgM, IgD | + | B | NA | Complex | G |
| 30 | Large, immunoblastic | CD45, CD30, CD38, CD71, HLA-DR | − | ID | NA | NA | NA |
| 31 | Large, pleomorphic | CD45, CD19, CD20, CD30, CD38, CD66, CD71, CD79a, EMA, LLC | + | B | NA | NA | G |
| 32 | Large, plasmacytoid | CD45, CD30, CD38, CD138, LLC | + | B | NA | NA | NA |
| 33 | NA | CD10, CD19 | NA | B | R | NA | NA |
| 34 | Medium to large, plasmacytoid | CD20, CD79a, LLC | + | B | NA | NA | NA |
| 35 | Large, pleomorphic | CD20 | − | B | NA | NA | NA |
| 36 | Large, pleomorphic | CD45, CD10, CD38 | + | B | R | NA | R |
| 37 | Medium to large | CD20, high Ki67 | − | B | NA | NA | NA |
| 38 | Large, pleomorphic to centroblastic | CD45, CD20, CD79a, BCL2, BCL6, MUM1 | − | B | R | NA | NA |
| 39 | Medium to large | CD5, CD19, CD20, CD25, LLC, IgM, IgD | − | B | R | NA | G-A |
| 40 | Medium to large | CD20 | − | B | R | Complex | G |
| 41 | Large, pleomorphic | CD45, CD20, CD79a, CD138, BOB1, OCT2, BCL6, MUM1 | − | B | NA | NA | NA |
| 42 | Large, pleomorphic | CD45, CD38, CD79a, CD138, PAX5, BOB1, OCT2, KLC | − | B | R | Constitutional paracentric inversion 10q | NA |
| 43 | Large, pleomorphic | CD45, CD38, CD56, CD138, KLC, Ki67 > 90% | + | B | G | NA | NA |
| 44 | Large, pleomorphic | CD45, CD20, CD30, CD43, BCL2 | − | B | NA | NA | NA |
| 45 | Large, plasmablastic | CD45, CD25, CD30, CD38, BLIMP1, granzyme, MUM1, TIA1 | − | B | NA | NA | NA |
G indicates germline; G-A, germline but amplified; ID, indeterminate; KLC, κ light chain restricted; LLC, λ light chain restricted; NA, not applicable; Ph/Ge, phenotype/genotype; R, rearranged.